NLY01
Parkinson's Disease
About Neuraly
Neuraly is a private, clinical-stage biotech pioneering novel therapeutics for neurodegenerative diseases. Its lead asset, NLY01, is a long-acting GLP-1R agonist currently in Phase 2 trials for both Parkinson's and Alzheimer's disease, with a mechanism centered on modulating neuroinflammation by targeting microglia and astrocytes. The company's pipeline also includes earlier-stage, orally active small molecules (NLY02, NLY03) targeting similar pathways, positioning Neuraly in the competitive but high-potential neurotherapeutics space. Its strategy leverages a well-known drug class (GLP-1 agonists) for new CNS indications to potentially derisk and accelerate development.
View full company profileAbout Neuraly
Neuraly is a private, clinical-stage biotech pioneering novel therapeutics for neurodegenerative diseases. Its lead asset, NLY01, is a long-acting GLP-1R agonist currently in Phase 2 trials for both Parkinson's and Alzheimer's disease, with a mechanism centered on modulating neuroinflammation by targeting microglia and astrocytes. The company's pipeline also includes earlier-stage, orally active small molecules (NLY02, NLY03) targeting similar pathways, positioning Neuraly in the competitive but high-potential neurotherapeutics space. Its strategy leverages a well-known drug class (GLP-1 agonists) for new CNS indications to potentially derisk and accelerate development.
View full company profileTherapeutic Areas
Other Parkinson's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| NPT200-11 | Neuropore Therapies | Phase 1 |
| VXX-301 | Vaxxinity | Preclinical |
| BAN2802 | BioArctic | Phase 1 |
| CNM-Au8 | Clene | Phase 2 |
| hpSC-Derived Neural/Dopaminergic Cells | International Stem Cell | Preclinical/Early Clinical |
| SLS-004 | Seelos Therapeutics | Preclinical |
| SLS-007 | Seelos Therapeutics | Preclinical |
| Parkinson's Disease Research | ProgenaBiome | Research |
| A9 Dopaminergic Neuron Therapy | Trailhead Biosystems | Pre-clinical |
| golexanolone | Umecrine Cognition | Preclinical |
| Parkin Activator Program | Progenra | Pre-clinical |
| Not Specified | Asceneuron | Not Disclosed |